In this Chicago Tribune post, G2P Director Robert Green writes that Hemsworth and Jolie are accelerating awareness and acceptance of a future where we do not wait to respond to the ravages of so many diseases but rather anticipate, predict and prevent them through genomics.
The first major randomized clinical trial on the effect of disclosing genetic information found that people who decided to learn about their genetic risk of developing Alzheimer’s disease did not experience large, negative psychological impacts.
Dr. Robert Green and Kreg Klugman explore the pros and cons of knowing one’s risk for developing Alzheimer’s.
MIT scientists used a novel tool to try to edit out a genetic risk for Alzheimer’s disease, they report in the journal Science. Dr. Robert Green gives his opinion on the new technology.
Dr. Robert Green on learning of your genetic risk to developing Alzheimer’s quotes: “Not everything has a pill or medical-prevention plan, but many information-seeking persons can find all sorts of benefits in better understanding their risk of future disease.”
Book
Dr. Robert C. Green speaks at the 2018 Advances in Genome Biology and Technology (AGBT) Precision Health Conference in San Diego, California about our efforts to gather empirical data on genome sequencing healthy individuals. Watch to learn more about G2P’s MilSeq, BabySeq, MedSeq, PeopleSeq, PGen and REVEAL projects. Click here for more on the conference.
In spring, The New York Times highlighted G2P’s work with REVEAL-SCAN, team members participated in a 10k marathon to raise money for genetic research, and G2P researchers published a new article on direct-to-consumer testing.
Dr. Green has found that people who learn they have the ApoE4 gene fare just as well if they get the results without counseling.those who learned they had the gene variant — Ms. Reilly was one of them — were nearly six times more likely to buy long-term care insurance than those who did not.
An overview and summary of the main projects that are being conducted within the G2P program, both past and present. This article also includes the progract managers and research assistants on each major project.
Within the REVEAL-SCAN study, one group of participants are given back the results on Alzheimer’s and additional heart disease information. Patients who are receiving the additional information are finding it reassuring that they can take measures to prevent at least one of their possible conditions if they have mutations for both.
Through the REVEAL study, researchers were testing to see how participants anxiety, depression, and test-related distress would be affected by knowing their genetic results of Alzheimer’s Disease and Coronary artery disease.
A new study has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer’s disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors. The results of the randomized controlled study are published online in the journal Annals of … Continued
The research study conducted through REVEAL might help researchers and doctors decide how much information to give patients based on genetic testing results
